XML 51 R38.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Income Before Income Tax, Domestic and Foreign

Loss before provision for income taxes includes the following components (in thousands):

 

 

Year Ended December 31,

 

 

2024

 

 

2023

 

Domestic

 

$

(119,227

)

 

$

(274,998

)

Foreign

 

 

27

 

 

 

(1,258

)

Loss before provision for income taxes

 

$

(119,200

)

 

$

(276,256

)

Schedule of Provision for Income Taxes

The provision for income taxes consists of the following (in thousands):

 

 

Year Ended December 31,

 

 

2024

 

 

2023

 

Current:

 

 

 

 

 

 

Federal

 

$

 

 

$

 

State

 

 

(277

)

 

 

(43

)

Foreign

 

 

48

 

 

 

(17

)

Total current income tax expense

 

 

(229

)

 

 

(60

)

Deferred:

 

 

 

 

 

 

Federal

 

 

 

 

 

 

State

 

 

 

 

 

 

Foreign

 

 

(10

)

 

 

(140

)

Total deferred income tax expense

 

 

(10

)

 

 

(140

)

Provision (benefit) for income taxes

 

$

(239

)

 

$

(200

)

Schedule of Income Tax Provision Related to Continuing Operations

Our income tax provision related to continuing operations differs from the amount computed by applying the statutory income tax rate of 21% to our pretax loss as follows (in thousands):

 

 

Year Ended December 31,

 

 

2024

 

 

2023

 

Income tax benefit at federal statutory rate

 

$

(25,032

)

 

$

(58,013

)

Research credits

 

 

7,741

 

 

 

(1,192

)

Change in valuation allowance

 

 

1,635

 

 

 

35,033

 

Expiration of net operating loss carryforwards

 

 

8,252

 

 

 

312

 

Stock-based compensation

 

 

4,280

 

 

 

8,919

 

Non-cash interest expense on liability related to sales of future royalties

 

 

5,904

 

 

 

5,320

 

Non-cash royalty revenue related to sales of future royalties

 

 

(5,645

)

 

 

(7,838

)

Impairment of goodwill

 

 

 

 

 

16,065

 

Other

 

 

2,626

 

 

 

1,194

 

Provision (benefit) for income taxes

 

$

(239

)

 

$

(200

)

Schedule of Significant Components of Deferred Tax Assets and Liabilities We measure deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands):

 

 

December 31,

 

 

2024

 

 

2023

 

Deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforwards

 

$

587,528

 

 

$

574,737

 

Research and other credits

 

 

135,871

 

 

 

144,128

 

Net capital loss carryforwards

 

 

39,648

 

 

 

39,655

 

Operating lease liabilities

 

 

22,767

 

 

 

25,384

 

Stock-based compensation

 

 

19,619

 

 

 

19,447

 

Capitalized research and development costs

 

 

45,607

 

 

 

34,675

 

Liability related to the sale of future royalties

 

 

2,020

 

 

 

6,729

 

Other

 

 

9,402

 

 

 

13,863

 

Deferred tax assets before valuation allowance

 

 

862,462

 

 

 

858,618

 

Valuation allowance for deferred tax assets

 

 

(859,084

)

 

 

(854,528

)

Total deferred tax assets

 

 

3,378

 

 

 

4,090

 

Deferred tax liabilities:

 

 

 

 

 

 

Operating lease right-of-use assets

 

 

(1,835

)

 

 

(3,824

)

Investment in foreign subsidiary

 

 

(511

)

 

 

(521

)

Outside basis difference in Gannet BioChem

 

 

(1,337

)

 

 

 

Other

 

 

(205

)

 

 

(265

)

Total deferred tax liabilities

 

 

(3,888

)

 

 

(4,610

)

Net deferred tax assets (liabilities)

 

$

(510

)

 

$

(520

)

Schedule of Unrecognized Tax Benefits

We have the following activity relating to unrecognized tax benefits (in thousands):

 

 

Year Ended December 31,

 

 

2024

 

 

2023

 

Beginning balance

 

$

126,498

 

 

$

85,845

 

Tax positions related to current year:

 

 

 

 

 

 

Additions

 

 

582

 

 

 

848

 

Reductions

 

 

 

 

 

 

Tax positions related to prior years:

 

 

 

 

 

 

Additions

 

 

10,101

 

 

 

40,079

 

Reductions

 

 

(16

)

 

 

 

Settlements

 

 

(815

)

 

 

 

Lapses in statute of limitations

 

 

(678

)

 

 

(274

)

Ending balance

 

$

135,672

 

 

$

126,498